{"id":71773,"date":"2026-08-06T00:28:24","date_gmt":"2026-08-05T16:28:24","guid":{"rendered":"https:\/\/flcube.com\/?p=71773"},"modified":"2026-08-06T00:28:26","modified_gmt":"2026-08-05T16:28:26","slug":"biogen-reports-q2-2026-revenue-of-2-74b-growth-portfolio-surges-24-led-by-strong-leqembi-and-skyclarys-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71773","title":{"rendered":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) released its second-quarter 2026 financial results, reporting <strong>revenue of USD 2.736 billion<\/strong>, representing a <strong>3% year-over-year increase at constant exchange rates (CER)<\/strong>. The company&#8217;s <strong>Growth Portfolio generated USD 1.06 billion in revenue<\/strong>, up <strong>24% year-over-year<\/strong>, demonstrating strong momentum across its diversified pipeline of innovative therapies.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-snapshot\" class=\"wp-block-heading\">Financial Performance Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026<\/th><th>YoY Change (CER)<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD 2.736B<\/td><td>+3%<\/td><\/tr><tr><td><strong>Growth Portfolio Revenue<\/strong><\/td><td>USD 1.06B<\/td><td>+24%<\/td><\/tr><tr><td><strong>Growth Portfolio Contribution<\/strong><\/td><td>39% of total revenue<\/td><td>Significant expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-growth-portfolio-detailed-performance\" class=\"wp-block-heading\">Growth Portfolio Detailed Performance<\/h2>\n\n\n\n<h3 id=\"h-neurology-amp-rare-disease-leaders\" class=\"wp-block-heading\">Neurology &amp; Rare Disease Leaders<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPINRAZA<\/strong> (nusinersen): USD 402M (+2% YoY)<\/li>\n\n\n\n<li>Primary driver: High-dose regimen adoption exceeding expectations across all launched regions<\/li>\n\n\n\n<li>Indication: Spinal muscular atrophy (SMA)<\/li>\n\n\n\n<li><strong>LEQEMBI<\/strong> (lecanemab): USD 184M (+15% YoY)<\/li>\n\n\n\n<li><strong>U.S. sales<\/strong>: USD 97M with continued sequential growth<\/li>\n\n\n\n<li><strong>Regulatory milestone<\/strong>: FDA approval of <strong>LEQEMBI IQLIK<\/strong> for at-home initiation (first-of-its-kind anti-amyloid treatment)<\/li>\n\n\n\n<li>Indication: Early Alzheimer&#8217;s disease<\/li>\n\n\n\n<li><strong>SKYCLARYS<\/strong>: USD 168M (+29% YoY)<\/li>\n\n\n\n<li>Primary driver: Global demand growth from ongoing commercial launches in Europe and international markets<\/li>\n\n\n\n<li>Indication: Friedreich&#8217;s ataxia<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-recent-launch-success-stories\" class=\"wp-block-heading\">Recent Launch Success Stories<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ZURZUVAE<\/strong>: USD 71M (+53% YoY)<\/li>\n\n\n\n<li><strong>Geographic expansion<\/strong>: First commercial launch outside U.S. in Germany<\/li>\n\n\n\n<li>Significance: Marks initial international rollout for postpartum depression (PPD) treatment<\/li>\n\n\n\n<li><strong>SYFOVRE<\/strong>: USD 162M (+8% YoY)<\/li>\n\n\n\n<li><strong>Performance milestone<\/strong>: Strongest quarterly demand since launch<\/li>\n\n\n\n<li><strong>Acquisition impact<\/strong>: USD 97M recognized following Apellis acquisition close on May 14, 2026<\/li>\n\n\n\n<li>Indication: Geographic atrophy (GA) secondary to age-related macular degeneration<\/li>\n\n\n\n<li><strong>EMPAVELI<\/strong>: USD 46M (+123% YoY)<\/li>\n\n\n\n<li><strong>Acquisition contribution<\/strong>: USD 30M recognized by Biogen post-Apellis acquisition<\/li>\n\n\n\n<li>Indication: Paroxysmal nocturnal hemoglobinuria (PNH)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-portfolio-challenges\" class=\"wp-block-heading\">Portfolio Challenges<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>VUMERITY<\/strong>: USD 197M (-7% YoY)<\/li>\n\n\n\n<li><strong>Context<\/strong>: Impact from inventory dynamics despite 7% first-half growth<\/li>\n\n\n\n<li>Indication: Multiple sclerosis (MS)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-acquisition-integration\" class=\"wp-block-heading\">Strategic Acquisition Integration<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>Apellis Pharmaceuticals acquisition<\/strong>, completed on <strong>May 14, 2026<\/strong>, has immediately contributed to Biogen&#8217;s growth trajectory:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SYFOVRE<\/strong>: USD 97M in Q2 revenue recognition<\/li>\n\n\n\n<li><strong>EMPAVELI<\/strong>: USD 30M in Q2 revenue recognition<\/li>\n\n\n\n<li><strong>Portfolio diversification<\/strong>: Enhanced presence in ophthalmology and rare hematology<\/li>\n\n\n\n<li><strong>Integration status<\/strong>: Successful operational integration enabling immediate commercial contribution<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-dynamics-amp-competitive-positioning\" class=\"wp-block-heading\">Market Dynamics &amp; Competitive Positioning<\/h2>\n\n\n\n<h3 id=\"h-alzheimer-s-disease-leadership\" class=\"wp-block-heading\">Alzheimer&#8217;s Disease Leadership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LEQEMBI differentiation<\/strong>: At-home initiation capability provides significant patient convenience advantage<\/li>\n\n\n\n<li><strong>Market expansion<\/strong>: Continued U.S. growth with potential international opportunities<\/li>\n\n\n\n<li><strong>Competitive moat<\/strong>: First-mover advantage in anti-amyloid space with innovative delivery model<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-commercial-execution\" class=\"wp-block-heading\">Global Commercial Execution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International success<\/strong>: Strong performance in European and global markets across multiple products<\/li>\n\n\n\n<li><strong>Launch excellence<\/strong>: Effective commercial execution for recent product introductions<\/li>\n\n\n\n<li><strong>Geographic diversification<\/strong>: Reduced dependency on U.S.-only revenue streams<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-area-breadth\" class=\"wp-block-heading\">Therapeutic Area Breadth<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neurology dominance<\/strong>: Continued leadership in SMA, MS, and Alzheimer&#8217;s disease<\/li>\n\n\n\n<li><strong>Rare disease expansion<\/strong>: Growing footprint in Friedreich&#8217;s ataxia, PPD, and PNH<\/li>\n\n\n\n<li><strong>Ophthalmology entry<\/strong>: New presence in geographic atrophy through Apellis acquisition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-outlook-amp-strategic-priorities\" class=\"wp-block-heading\">Forward Outlook &amp; Strategic Priorities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Growth Portfolio acceleration<\/strong>: On track to exceed full-year guidance based on H1 momentum<\/li>\n\n\n\n<li><strong>LEQEMBI commercial expansion<\/strong>: At-home initiation expected to drive further adoption<\/li>\n\n\n\n<li><strong>International launch pipeline<\/strong>: Multiple products in various stages of global rollout<\/li>\n\n\n\n<li><strong>Integration benefits<\/strong>: Full-year contribution from Apellis assets expected in H2 2026<\/li>\n\n\n\n<li><strong>Pipeline catalysts<\/strong>: Additional regulatory submissions and commercial launches anticipated<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, regulatory approvals, and commercial launches. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/BIOGEN-Q2-2026-Earnings-Press-Release_Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BIOGEN Q2 2026 Earnings Press Release_Final.\"><\/object><a id=\"wp-block-file--media-d185acb2-6b91-41e4-877b-8c42f62f1c0d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/BIOGEN-Q2-2026-Earnings-Press-Release_Final.pdf\">BIOGEN Q2 2026 Earnings Press Release_Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/BIOGEN-Q2-2026-Earnings-Press-Release_Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d185acb2-6b91-41e4-877b-8c42f62f1c0d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71775,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[351,27,993],"class_list":["post-71773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biogen","tag-finanical-reports","tag-nasdaq-biib"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company&#039;s Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71773\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company&#039;s Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71773\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:28:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:28:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance\",\"datePublished\":\"2026-08-05T16:28:24+00:00\",\"dateModified\":\"2026-08-05T16:28:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773\"},\"wordCount\":528,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0508.webp\",\"keywords\":[\"Biogen\",\"Finanical Reports\",\"NASDAQ: BIIB\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71773#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71773\",\"name\":\"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0508.webp\",\"datePublished\":\"2026-08-05T16:28:24+00:00\",\"dateModified\":\"2026-08-05T16:28:26+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company's Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71773\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0508.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0508.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71773#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company's Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71773","og_locale":"en_US","og_type":"article","og_title":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance","og_description":"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company's Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.","og_url":"https:\/\/flcube.com\/?p=71773","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:28:24+00:00","article_modified_time":"2026-08-05T16:28:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71773#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71773"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance","datePublished":"2026-08-05T16:28:24+00:00","dateModified":"2026-08-05T16:28:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71773"},"wordCount":528,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","keywords":["Biogen","Finanical Reports","NASDAQ: BIIB"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71773#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71773","url":"https:\/\/flcube.com\/?p=71773","name":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71773#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","datePublished":"2026-08-05T16:28:24+00:00","dateModified":"2026-08-05T16:28:26+00:00","description":"Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company's Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71773#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71773"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71773#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","width":1080,"height":608,"caption":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71773#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0508.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71773"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71773\/revisions"}],"predecessor-version":[{"id":71776,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71773\/revisions\/71776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71775"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}